EGFR and non-small cell lung carcinoma: Indeed, in recent in vitro studies, conducted on the human NSCLC HCC827 cell line (harboring the activating EGFR mutation in exon 19) and made resistant to gefitinib, revealed that MET became amplified and caused resistance to TKI through an ErbB3-dependent activation of PI3K [33,34].